This article is more than 5 years old. Information may no longer be current.

VIDEO: CLS-TA, aflibercept combo reduced treatment burden compared with aflibercept alone

ByArshad Khanani, MD, MA, FASRS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — At the Retina World Congress, Arshad M. Khanani, MD, MA, discusses results from the phase 2 prospective randomized TYBEE study, which showed that CLS-TA (Clearside Biomedical) in combination with aflibercept had similar visual acuity outcomes, lessened fluid as seen on OCT and reduced the number of injections needed compared with aflibercept alone.